Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 14/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 14/20 | 0.58 |
| ▸ | P2RY12 | Q9H244 | 11/20 | 0.58 |
| ▸ | PDE2A | O00408 | 5/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8499648 | 0.88 | PDE3B (0.55) | PDE3BPDE3AP2RY12PDE2APDGFRB | |
| SCHEMBL8499164 | 0.83 | PDGFRB (0.52) | PDE3BPDE3AP2RY12PDGFRBPDGFRA | |
| SCHEMBL8502489 | 0.83 | PDGFRB (0.52) | PDE3BPDE3AP2RY12PDE2APDGFRB | |
| SCHEMBL8501205 | 0.81 | PDGFRB (0.51) | PDGFRBPDGFRA | |
| Hydrochloric Acid SCHEMBL8503310 | 0.80 | PDGFRB (0.52) | PDE3BPDE3AP2RY12PDE2APDGFRB | |
| SCHEMBL8887119 | 0.80 | PDGFRB (0.47) | PDE3BPDE3AP2RY12PDGFRBPDGFRA | |
| Hydrochloric Acid SCHEMBL8504144 | 0.79 | PDGFRB (0.51) | PDGFRBPDGFRA | |
| SCHEMBL8887112 | 0.77 | PDGFRB (0.45) | PDE3BPDE3AP2RY12PDE2APDGFRB | |
| SCHEMBL6328915 | 0.77 | MRGPRX4 (0.52) | PDE3BPDE3AP2RY12PDE2A | |
| SCHEMBL8503378 | 0.77 | PDGFRB (0.57) | PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | claimed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |